Switch theme
Sign up to access all valuation multiples
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
1983
11K+
LTM Revenue $4.0B
LTM EBITDA $1.4B
$42.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IDEXX Laboratories has a last 12-month revenue (LTM) of $4.0B and a last 12-month EBITDA of $1.4B.
In the most recent fiscal year, IDEXX Laboratories achieved revenue of $3.9B and an EBITDA of $1.3B.
IDEXX Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IDEXX Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0B | XXX | $3.9B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $928M | XXX | $888M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $579M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IDEXX Laboratories's stock price is $513.
IDEXX Laboratories has current market cap of $41.3B, and EV of $42.2B.
See IDEXX Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42.2B | $41.3B | XXX | XXX | XXX | XXX | $11.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IDEXX Laboratories has market cap of $41.3B and EV of $42.2B.
IDEXX Laboratories's trades at 10.8x EV/Revenue multiple, and 33.2x EV/EBITDA.
Equity research analysts estimate IDEXX Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IDEXX Laboratories has a P/E ratio of 44.5x.
See valuation multiples for IDEXX Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $41.3B | XXX | $41.3B | XXX | XXX | XXX |
| EV (current) | $42.2B | XXX | $42.2B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBITDA | 31.2x | XXX | 33.2x | XXX | XXX | XXX |
| EV/EBIT | 35.2x | XXX | 37.4x | XXX | XXX | XXX |
| EV/Gross Profit | 17.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 44.5x | XXX | 46.5x | XXX | XXX | XXX |
| EV/FCF | 47.6x | XXX | 52.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIDEXX Laboratories's last 12 month revenue growth is 7%
IDEXX Laboratories's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
IDEXX Laboratories's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IDEXX Laboratories's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IDEXX Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IDEXX Laboratories acquired XXX companies to date.
Last acquisition by IDEXX Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . IDEXX Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IDEXX Laboratories founded? | IDEXX Laboratories was founded in 1983. |
| Where is IDEXX Laboratories headquartered? | IDEXX Laboratories is headquartered in United States of America. |
| How many employees does IDEXX Laboratories have? | As of today, IDEXX Laboratories has 11K+ employees. |
| Who is the CEO of IDEXX Laboratories? | IDEXX Laboratories's CEO is Mr. Jonathan J. Mazelsky. |
| Is IDEXX Laboratories publicy listed? | Yes, IDEXX Laboratories is a public company listed on NAS. |
| What is the stock symbol of IDEXX Laboratories? | IDEXX Laboratories trades under IDXX ticker. |
| When did IDEXX Laboratories go public? | IDEXX Laboratories went public in 1991. |
| Who are competitors of IDEXX Laboratories? | Similar companies to IDEXX Laboratories include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of IDEXX Laboratories? | IDEXX Laboratories's current market cap is $41.3B |
| What is the current revenue of IDEXX Laboratories? | IDEXX Laboratories's last 12 months revenue is $4.0B. |
| What is the current revenue growth of IDEXX Laboratories? | IDEXX Laboratories revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of IDEXX Laboratories? | Current revenue multiple of IDEXX Laboratories is 10.6x. |
| Is IDEXX Laboratories profitable? | Yes, IDEXX Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IDEXX Laboratories? | IDEXX Laboratories's last 12 months EBITDA is $1.4B. |
| What is IDEXX Laboratories's EBITDA margin? | IDEXX Laboratories's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of IDEXX Laboratories? | Current EBITDA multiple of IDEXX Laboratories is 31.2x. |
| What is the current FCF of IDEXX Laboratories? | IDEXX Laboratories's last 12 months FCF is $886M. |
| What is IDEXX Laboratories's FCF margin? | IDEXX Laboratories's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of IDEXX Laboratories? | Current FCF multiple of IDEXX Laboratories is 47.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
